Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure

Bechis, Mary Z.; Rubenson, David; Price, Matthew J.

doi:10.1016/j.iccl.2017.05.004

Cited by 8 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is necessary in qualification and monitoring of interventional procedures as well as in follow -up, with particular emphasis on peri-and postoperative complications. [14][15][16][17] Transthoracic echocardiography (TTE) enables not only the recognition of the defect, but also the assessment of shunt hemodynamic significance. Transesophageal echocardiography (TEE) is required in terms of inconclusive TTE or during qualification for percutaneous interventions.…”

Section: Noninvasive Diagnostics Echocardiographymentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous closure of atrial septal defect: a consensus document of the joint group of experts from the Association of Cardiovascular Interventions and the Grown-Up Congenital Heart Disease Section of the Polish Cardiac Society

et al. 2020

View full text Add to dashboard Cite

communication. There are 5 types of anatomic defects known: • Secundum ASD (ASD II): 80% to even more than 90% of ASDs in the adult population; located in the fossa ovalis region and its surrounding tissue. Background information on atrial septal defect Atrial septal defect (ASD) is one of the most prevalent congenital heart defects and may frequently remain undiagnosed until adulthood. 1-4 It is a consequence of various embryological disorders that cause interatrial

show abstract

Section: Noninvasive Diagnostics Echocardiographymentioning

confidence: 99%

“…It is necessary to determine and verify the number, size, and shape of defects and their spatial relation to the surrounding structures. [14][15][16][17] It is pivotal to evaluate rims-the aortic rim is the only one not obligatory for percutaneous closure. All other rims should be at least 5 mm, although in addition to length, their quality is also important.…”

mentioning

confidence: 99%

Percutaneous closure of atrial septal defect: a consensus document of the joint group of experts from the Association of Cardiovascular Interventions and the Grown-Up Congenital Heart Disease Section of the Polish Cardiac Society

et al. 2020

View full text Add to dashboard Cite

show abstract

“…There was a higher prevalence of septal aneurysm among patients that underwent closure with ASO devices (32% vs. 25%, p = 0.061) which might partially explain the greater residual shunt detected with ASO in the peri-procedural transesophageal echocardiography. Preprocedural screening and diagnosis of septal anomalies with transesophageal echocardiography has demonstrated an excellent specificity to diagnose and measure interatrial shunts [21][22][23] but also might be useful in determining which device is optimal for each patient. According to the present findings, those patients with baseline risk of residual shunt (i.e.…”

Section: Baseline Risk and Post-procedural Main Complicationsmentioning

confidence: 99%

Comparison of Figulla Flex® and Amplatzer™ devices for atrial septal defect closure: A meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Atrial septal defect (ASD) is one of the most common congenital heart diseases. Percutaneous closure is the preferred treatment, but certain complications remain a concern. The most common devices are AMPLATZER™ (ASO) (St. Jude Medical, St. Paul, MN, USA) and Figulla Flex ® septal occluders (FSO) (Occlutech GmbH, Jena, Germany). The present study aimed to assess main differences in outcomes. Methods: A systematic search in Pubmed and Google scholarship was performed by two independent reviewers for any study comparing ASO and FSO. Searched terms were "Figulla", "Amplatzer", and "atrial septal defect". A random-effects model was used. Results: A total of 11 studies including 1770 patients (897 ASO; 873 FSO) were gathered. Baseline clinical and echocardiographic characteristics were comparable although septal aneurysm was more often reported in patients treated with ASO (32% vs. 25%; p = 0.061). Success rate (94% vs. 95%; OR: 0.81; 95% CI: 0.38-1.71; p = 0.58) and peri-procedural complications were comparable. Procedures were shorter, requiring less fluoroscopy time with an FSO device (OR: 0.59; 95% CI: 0.20-0.97; p = 0.003). Although the global rate of 2 complications in long-term was similar, the ASO device was associated with a higher rate of supraventricular arrhythmias (14.7% vs. 7.8%, p = 0.009). Conclusions: Percutaneous closure of ASD is a safe and effective, irrespective of the type of device. No differences exist regarding procedural success between the ASO and FSO devices but the last was associated to shorter procedure time, less radiation, and lower rate of supraventricular arrhythmias in follow-up. Late cardiac perforation did not occur and death in the follow-up was exceptional.

show abstract

“…During a PFO closure procedure, TEE is used in combination with fluoroscopy (Bartel and Müller 2013;Bechis et al 2017;Faletra et al 2014;Karsenty et al 2018;Silvestry et al 2015). Both 2-D-TEE and 3-D-TEE enable display of the long segments of the catheters and wires and their relationship to adjacent and surrounding anatomic structures, helping the manipulation of the device.…”

Section: Intra-procedural Guidancementioning

confidence: 99%

“…It has been implicated in a number of pathologies, such as cryptogenic stroke, platypneaÀorthodeoxia syndrome, decompression sickness, and migraine with auras (Mojadidi et al 2018). Developments in bioengineering have made percutaneous transcatheter closure of PFO a safe treatment option (Ahmad et al 2018;Wictor and Carroll 2018), and intraprocedural guidance of transesophageal echocardiography (TEE) is common (Bechis et al 2017;Silvestry et al 2015). The superiority of device closure over medical therapy for the prevention of recurrent strokes in patients with cryptogenic stroke and a PFO was reported in four recent randomized controlled trials (Lee et al 2018;Mas et al 2017, Saver at al.…”

Section: Introductionmentioning

confidence: 99%

Patent Foramen Ovale: Pivotal Role of Transesophageal Echocardiography in the Indications for Closure, Assessment of Varying Anatomies and Post-procedure Follow-up

Vitarelli

2019

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

Patent foramen ovale (PFO) is present in 15%À30% of the general population and has been associated with various pathologic states, including cryptogenic stroke, platypneaÀorthodeoxia syndrome, decompression sickness and migraine with auras. Transesophageal echocardiography (TEE) has a major role in the diagnostic evaluation of PFO, as well as in the post-procedural assessment after transcatheter closure. The goals of this article were to synthesize the echocardiographic transesophageal techniques required for accurate PFO diagnosis and careful anatomic assessment of its anatomic variants, to focus TEE indications for device closure as complementary to clinical indications and to assess the role of TEE in the post-procedure follow-up.

show abstract

Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure

Cited by 8 publications

References 32 publications

Percutaneous closure of atrial septal defect: a consensus document of the joint group of experts from the Association of Cardiovascular Interventions and the Grown-Up Congenital Heart Disease Section of the Polish Cardiac Society

Percutaneous closure of atrial septal defect: a consensus document of the joint group of experts from the Association of Cardiovascular Interventions and the Grown-Up Congenital Heart Disease Section of the Polish Cardiac Society

Comparison of Figulla Flex® and Amplatzer™ devices for atrial septal defect closure: A meta-analysis

Patent Foramen Ovale: Pivotal Role of Transesophageal Echocardiography in the Indications for Closure, Assessment of Varying Anatomies and Post-procedure Follow-up

Contact Info

Product

Resources

About